Vishal Patel, MD
Interventional Cardiology · Santa Rosa, CANPI 1144455825
Payments from drug & device makers
Across 401 payments — averaging $178.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$57K
- Edwards Lifesciences$6K
- Abbott$5K
- Boston Scientific$448
- Novartis$266
- Abiomed$259
- plus $3K from 32 others
Across 1 payment — averaging $2600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$3K
What the payments were for
- Consulting fees$5251%
- Speaking & faculty fees$51,58372%
- Travel & lodging$6,0378%
- Food & beverage$13,50919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 115 | $56,821 |
| Edwards Lifesciences | 90 | $6,235 |
| Abbott | 55 | $5,102 |
| Boston Scientific | 15 | $448 |
| Novartis | 23 | $266 |
| Abiomed | 7 | $259 |
| Regeneron | 2 | $230 |
| Pfizer | 9 | $178 |
| Actelion Pharmaceuticals US, Inc. | 7 | $172 |
| Boehringer Ingelheim | 3 | $165 |
| United Therapeutics Corporation | 6 | $160 |
| Shockwave Medical, Inc | 2 | $156 |
| Amgen | 8 | $143 |
| Angiodynamics, Inc. | 1 | $142 |
| E.r. Squibb & Sons, L.L.C. | 6 | $121 |
| Bardy Diagnostics, Inc. | 5 | $111 |
| Esperion Therapeutics, Inc. | 4 | $98 |
| AstraZeneca | 6 | $95 |
| Johnson & Johnson | 5 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $80 |
| Philips North America LLC | 3 | $77 |
| Alnylam Pharmaceuticals Inc. | 3 | $70 |
| Bayer | 2 | $63 |
| Octapharma USA, Inc. | 2 | $36 |
| Bridgebio Pharma, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Heartflow, Inc. | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Irhythm Technologies, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Terumo Medical Corporation | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Preventice Services, LLC | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$21,352
- CoreValve Evolut$7,604
- ONYX FRONTIER$5,220
- VenaSeal$2,600
- RESOLUTE ONYX$2,340
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,013
- Mitra Clip system$917
- ENSITE PRECISION$762
- MITRIS RESILIA Mitral Valve$254
- SelectSecure$252
- CardioMEMS HF System$216
- Reveal LINQ$167
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- SAPIEN 3 Ultra RESILIA$140
- OPTIS$130
- Impella$126
- Micra$124
- MitraClip System$124
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$116
How this compares
$71,654 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 19 | $585,132 |
| EliquisApixaban | 432 | $580,223 |
| JardianceEmpagliflozin | 192 | $257,089 |
| EntrestoSacubitril/Valsartan | 177 | $252,146 |
| Repatha SureclickEvolocumab | 103 | $111,105 |
| XareltoRivaroxaban | 49 | $61,923 |
| Praluent PenAlirocumab | 32 | $33,630 |
| Repatha SyringeEvolocumab | 25 | $27,677 |
| OzempicSemaglutide | 16 | $15,116 |
| NexlizetBempedoic Acid/Ezetimibe | 18 | $10,908 |
| Ezetimibe | 246 | $10,074 |
| Atorvastatin Calcium | 712 | $8,881 |
| Valsartan | 234 | $7,488 |
| BrilintaTicagrelor | 12 | $6,902 |
| Rosuvastatin Calcium | 248 | $5,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $178 | $1,165,355451 claims |
| Boehringer IngelheimJardiance | $165 | $257,089192 claims |
| NovartisEntresto | $266 | $252,146177 claims |
| Johnson & JohnsonXarelto | $88 | $61,92349 claims |
| Esperion Therapeutics, Inc.Nexlizet | $98 | $10,90818 claims |
| AstraZenecaBrilinta | $95 | $6,90212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Santa Rosa
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.